REFERENCES
- DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
- American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 1998; 21 Suppl 1: S69–71.
- Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1021–5.
- Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of dia-betic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17.
- UKPDS group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes. The Lancet 1998; 352: 854–65.
- UKPDS group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet 1998; 352: 837–53.
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care 1998; 21 Suppl 1: S23–31.
- DCCT Research group. The diabetes control and complications trial (DCCT). Design and metho-dologic considerations for the feasibility phase. Diabetes 1986; 35: 531–45.
- Dunn P, Cole R, Soeldner J. Further development and automation of a high-pressure liquid chro-matography method for the determination of glycosylated hemoglobins. Metabolism 1979; 28: 777–9.
- Dybkaer R. Terminological problems around "accuracy" and "uncertainty". Scand J Clin Lab Invest 1998; 58: 35–46.
- Phillipou G, Phillips PJ. Intraindividual variation of glycohemoglobin: implications for interpreta-tion and analytical goals. Clin Chem 1993; 39: 2305–8.
- Fraser C. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27: 409–37.
- Guthrie R, Hellman R, Kilo C, et al. A multisite physician's office laboratory evaluation of an immunological method for the measurement of HbAlc. Diabetes Care 1992; 15: 1494–8.
- Larsen ML, Fraser G, Petersen PH. A comparison of analytical goals for haemoglobin A lc assays derived using different strategies. Ann Clin Biochem 1991; 28: 272–8.
- Penttild IM, Gävert J, Julkunen A, Rantanen T. Quality specifications for glycated hemoglobin A lc. Upsala J Med Sci 1993; 98: 395–9.
- Larsen M. The clinical usefulness of glucated haemoglobin in diabetes care evaluated by use of a medical technology assessment strategy. Dan Med Bull 1997; 44: 303–15.
- Expert Committee on the Diagnosis and Classifi-cation of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97.
- Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998; 15: 539–53.
- Engelgau M, Thompson T, Herman W, et al. Comparison of fasting and 2-hour glucose and HbAlc levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785–91.
- Gilbert RE, Goodall I, Young V, Jerums G. Interlaboratory variation of GHb assays in Victoria, Australia. Diabetes Care 1996; 19: 730–4.
- Kilpatrick ES. Problems in the assessment of glycemic contol in diabetes mellitus. Diabetic Med 1997; 14: 819–31.
- Kilpatrick ES, Maylor PW, Keevil BG. Biologic variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998; 21: 261–4.
- Kullberg CA, Bergstrom A, Dinesen B, et al. Comparison of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996; 19: 726–9.
- Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus. An analysis using glycosylated hemoglobin levels. JAMA 1996; 276: 1246— 52.
- Stewart M. Will glycosylated haemoglobin replace the oral glucose-tolerance test? Lancet 1997; 349: 223 — 4.
- Tsuji I, Nakamoto K, Hasegawa T, et al. Receiver operating characteristic analysis on fasting plasma glucose, HbAlc, and fructosamine on diabetes screening. Diabetes Care 1991; 14: 1075–7.